CT
ABMD

Chicago Trust’s Abiomed Inc ABMD Stock Holding History

Chicago Trust’s Portfolio ABMD Stock Details ABMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,047
Closed -$257K – 314
2022
Q3 		$257K Hold
1,047
– – 0.07% 250
2022
Q2 		$259K Hold
1,047
– – 0.07% 252
2022
Q1 		$347K Sell
1,047
-50
-5% -$15.4K 0.07% 235
2021
Q4 		$394K Buy
1,097
+145
+15% +$49K 0.08% 235
2021
Q3 		$310K Buy
952
+255
+37% +$86.4K 0.07% 251
2021
Q2 		$218K Buy
+697
New +$214K 0.05% 298

Other funds holding ABMD

TRSOTSOK
Teachers Retirement System of the State of Kentucky Frankfort, Kentucky $12.9B AUM 31.03% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Rockefeller Capital Management
Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
AW
Avion Wealth The Woodlands, Texas $484M AUM 15.17% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Chicago Trust's ABMD Position: Q4 2022 in Review

Chicago Trust sold out of Abiomed Inc (ABMD) in Q4 2022, closing a stake of 1,047 shares — an estimated $257K sold.

Chicago Trust first reported a position in ABMD in Q2 2021 and held it in 6 quarters. The position peaked at $394K in Q4 2021. 8 funds tracked by Wall St. Rank hold ABMD as of Q4 2022.

  • Chicago Trust reported no remaining Abiomed Inc position as of Q4 2022 after selling out during the quarter.
  • Chicago Trust sold 1,047 Abiomed Inc shares in Q4 2022, an estimated $257K.
  • Chicago Trust first reported a position in Abiomed Inc in Q2 2021 and held it in 6 quarters.
  • Chicago Trust's Abiomed Inc position peaked at $394K in Q4 2021.
  • 8 funds tracked by Wall St. Rank held Abiomed Inc as of Q4 2022.

Based on Chicago Trust's 13F filing for Q4 2022, filed 12 Jan 2023.